News

First once-daily human glucagon-like peptide-1 analog for the treatment of type 2 diabetes can be used in combination with other oral anti-diabetic medications.

But is it the video game or staying alert and involved that is key?

If you look at the photo of what finally went into my personal bag to Haiti, it's hard to imagine how much thought and fretting and, frankly, geometric calculation was involved.

Researchers found that UV exposure resulted in greater positive affect, well-being, relaxation, and reduced pain levels when compared to non-UV exposure.

At the Lysosomal Disease Network World Symposium in Miami, Florida, Amicus Therapeutics presented preliminary data from a phase II trial of the novel oral drug Amigal (migalastat HCl), which is being investigated as a treatment for Fabry disease.

Velaglucerase alfa is a novel enzyme replacement therapy being evaluated as a treatment for people with type 1 Gaucher disease. At the recent Lysosomal Disease Network World Symposium, Ari Zimran, a researcher with the Gaucher Clinic at Shaare Zedek Medical Center in Jerusalem, Israel, presented analyses of velaglucerase alfa therapy in pediatric patients enrolled in a phase III double-blind study (TKT032).

New research on the potential anti-H. pylori and anti-inflammation in vivo effects of two lactobacillus strains from the human stomach may indicate a possible new treatment for H. pylori-associated diseases.

A multinational phase III trial of taliglucerase alfa (Uplyso) found that it improved several clinical indicators in patients with type 1 Gaucher disease. Unlike imiglucerase alfa, which is mammalian based, or velaglucerase alfa, which is human based, taliglucerase alfa is a plant-based enzyme replacement therapy.

The International Collaborate Gaucher Group (ICGG) Gaucher Registry, financially and logistically supported by Genzyme Corporation, tracks routine clinical outcomes for patients with Gaucher disease. Physicians from all over the world are welcome to submit patient data to the registry, regardless of treatment status, which is maintained confidentiality and used to help determine response to treatment or establish other trends among individuals with Gaucher disease. Neal Weinreb, University Research Foundation for Lysosomal Storage Disorders, Coral Springs, Florida, gave a presentation on �Long-term Data from the ICGG Gaucher Registry: 10 Years of Treatment� at the Lysosomal Disease Network World Symposium.

New technology may soon allow physicians to see 3-D images of the heart's arteries, simplifying and improving the diagnostic procedure.

Ginkgo biloba may increase an individual's risk for seizures, according to a team of researchers from the University of Bonn in Germany.

A new study that evaluates the ability of two lactobacillus strains to fight H. pylori infections may be a gateway for new treatments.

Two years ago, researchers in the biomedical engineering department at Boston University found that lethal doses of antibiotics can stimulate the production of reactive oxygen species molecules, free radicals that damage DNA, and protein and lipids in bacterial cells.

Over the past month, we've been monitoring reports that are coming back from friends who have been in Haiti providing care to try and get to places away from the hospital and hearing what they have been taking care of.

Through the haze of the severe symptoms migraine patients experience shines a new light of the possibility of protection from a deadly cancer.

With applications for recording everything from calorie intake to sleep habits, smartphones are an increasingly valuable tool for patients suffering from chronic migraines.

Doctors are relatively uninformed about healthcare systems, outcomes research or healthcare economics, specifically the costs of care and cost-benefit.

New findings from a 25-year study show that patients with schizophrenia have a mortality risk that is two to three times that of the general population.

Without a doubt, fear motivates many people in different situations. But is it really the best way to motivate people, to help them learn, and to make permanent changes?

Haiti trip, 5 days and counting. The overriding question, for me, has become, just how bad is it?

HCPLive blogger Jill Taylor revisits the Lancet's retraction of the controversial 1998 autism study, and points to some new research in this field.

Our expectations have changed a lot as we continue to see, every day, hundreds of tweets about current conditions.

What's been really important is for us to connect with the volunteers who've just returned from Haiti.

A court of criminal inquiry against the established religion first appeared in France in the 13th century and attained its full glory in 1484, under Queen Isabella of Spain, with the founding of the Supreme General Inquisition. A closer look at the inner workings of the Quality Assurance Committees affirms that history does, in fact, repeat itself.

While the FDA states "marijuana has a high potential for abuse, has no currently accepted medical use in treatment in the United States, and has a lack of accepted safety for use under medical supervision," studies have yielded mixed, though largely favorable, results. Studies assessing its use in cancer have even demonstrated its potential as a treatment option.

In conjunction with the Community Oncology Alliance, community oncologists throughout the United States have launched a national petition to urge President Obama and lawmakers to reverse drastic cuts in reimbursement for cancer care that were implemented by the Centers for Medicare and Medicaid Services (CMS) on January 1, 2010 and are slated to compound through 2013.

Recent study results indicate that women with gout face a greater risk of acute myocardial infarction than do men who have been diagnosed with gout.

Latino children received 30 percent less opioid analgesics than white children, most likely due to...

A front page article in the New York Times (January 24, 2010) described the harrowing tales of two patients who were harmed by radiation therapy errors.

This pair of webcasts features presentations on the role of linear ablation in treating atrial fibrillation and targets for non-ionic channel therapies.